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Abstract
Background: Asthma is increasing worldwide and results from a complex immunological interaction between
genetic susceptibility and environmental factors. Autovaccination with E. coli induces a strong TH-1 immune
response, thus offering an option for the treatment of allergic diseases.
Methods: Prospective open trial on safety, tolerability, and impact on allergic inflammation of an autologous E.coli
autovaccine in intermittent or mild persistent house dust mite asthma. Determination of exhaled nitric monoxide
(eNO) before and after bronchial mite challenge initially and after nine months of autovaccination.
Results: In nine subjects and a total of 306 injections, we observed 101 episodes of local erythema (33.3%; median
of maximal diameter 2.5 cm), 95 episodes of local swelling (31.1%; median of maximal diameter 3 cm), and 27
episodes of local pain (8.8%). Four subjects reported itching at the injection site with a total of 30 episodes (9.8%).
Median eNO increase after autovaccination was significantly smaller (from 27.3 to 33.8 ppb; p = 0.334) compared
to initial values (from 32.6 to 42.2 ppb; p = 0.046) (p = 0.034). We observed no serious adverse events. All organ
functions (inclusive electrocardiogramm) and laboratory testing of the blood (clinical chemistry, hematology) and
the urine (screening test, Β-microglobuline) were within normal limits. Vital signs undulated within the
physiological variability.
Conclusion: The administration of autologous autovacine for the treatment of house dust mite asthma resulted in
a reduction of the eNO increase upon bronchial mite challenge. In nine subjects and 306 injections, only a few
mild local reactions and no systemic severe adverse events were observed.
Trial registration: EudraCT Nr. 2005-005534-12
ClinicalTrials.gov ID NCT00677209
Keywords: autovaccine, safety, tolerability, house dust mite allergy, asthma
Background
Asthma is increasing worldwide and results from a com-
plex interaction between genetic susceptibility and
environmental factors. Autovaccination with E. coli
induces in animal models and in human studies a strong
TH-1 immune response. In allergic individuals, this
immunization can cause a shift from TH-2- to TH-1-
dominated immune response, and has the potential to
work as an unspecific immunotherapy, evoking immu-
notolerance [1].
Allergic diseases such as rhinoconjunctivitis or bron-
chial asthma are a major burden of disease, requiring
evidence-based therapy concepts. So far, treatment
mainly encompasses antiallergics, anti-inflammatory
drugs (e.g., steroids), or bronchodilators. The only cau-
sative therapeutic option is the specific immunotherapy
(SIT), administering the patient the relevant allergen in
increasing doses [2], thus inducing immunotolerance. * Correspondence: Markus.Rose@kgu.de
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allergenspecific T-cell suppression directed against the
house dust mite allergen Der p1 is observed. In allergics,
this TH1 (IFN-y)-immunresponse is reduced, with a
shift towards a TH2-dominated (IL-5, IL-13) immune
pattern. Neutralization tests of cytokine activity revealed
that the T-cell-suppression in specific immunotherapy
and immunotolerance against mucosal antigens is
induced by IL-10 and TGF-ß. In addition, specific
immunotherapy results in an antigenspecific suppressive
activity in CD4(+) CD25(+)-T-cells of allergic subjects.
In conclusion, during SIT a shift towards a regulatory/
suppressor-T-Zell-response (TH-1) can be observed,
which is a key phenomenon for the induction of immu-
notolerance. One must admit, that depending on the
age and individual features of house dust mite allergics,
SIT is of heterogeneous efficiency [3], demanding even
more therapeutic alternatives.
The determination of exhaled nitric oxide (eNO) is an
established tool to monitor bronchial inflammation. We
used the increase of eNO following specific bronchial
provocation with house dust mite extract before and
after the autovaccine treatment as a surrogate for the
autovaccine’s potential impact on allergic asthma. In the
last decades, bacterial autovaccines have been used in
general medicine worldwide [4-12]. Despite their broad
use for many indications (e.g., chronic infections), no
studies according to good clinical practice have been
performed. This is the first prospective study to investi-
gate the safety, tolerability, and impact on allergic
inflammation of an autologous E. coli autovaccine in
patients with house dust mite allergy and bronchial
asthma.
Methods
Participants
In our investigator-initiated prospective study, a total of
nine subjects were recruited from our walk-in clinic.
Included were clinically healthy 18-50 year old asth-
matics (GINA 0-1°; episodic bronchial obstruction, on-
demand therapy only) with skin prick test and bronchial
challenge positive for house dust mite (FEV1 decrease ≥
20%). Exclusion criteria were a history of intolerance
towards the ingredients of the autovaccine, asthma
≥GINA II°, other chronic infections/diseases, pregnancy,
intermittent treatment with systemic steroids or perma-
nent treatment with inhalative steroids, other immun-
modulation or -suppression, any known substance
abuse, the incapability to understand and perform the
study, and tobacco smoking. Women of childbearing
age were instructed to perform contraception. All parti-
cipants supplied written informed consent prior to the
study. Human experimentation guidelines of Good Clin-
ical Practice, the German Drug Act and the declaration
of Helsinki/Hong Kong were followed in the conduct of
clinical research. The study had been approved by the
ethical committee of the University of Frankfurt.
Study design and assessment
Included participants underwent a 37 week protocol
with autologous E. coli autovaccine being subcuta-
neously applied in incremental doses as established in
clinical routine practise (see figure 1). At the beginning
of every visit, body temperature was determined and a
physical examination performed. Between visits 12 and
13, 24 and 25, and 36 and 37 a 4-week-break was
included to facilitate immunological conditioning. At
every visit, a screening for kidney function was per-
formed (Combur-Test
®, Fa. Roche Diagnostics; detec-
tion of leucocytes, nitric, pH, protein, glucose, ketones,
urobilinogen, bilirubin, blood, and hemoglobine). At
visit 0, 18 (-in the middle of the intervention), and 38,
additionally beta-microglobuline was determined as tub-
ular marker. At visit 0, 18, and 38, also an electrocardio-
gram was performed. After every injection, participants
were monitored clinically (heart rate, body temperature,
and blood pressure) every 30 minutes for two hours.
Measuring of body temperature and peak flow was con-
tinued at home until 12 hours after the injection.
Adverse events were recorded with the trial diary. At
visit 0 and 37 (after the intervention), specific bronchial
provocation and measurement of eNO were performed
to assess the potential impact of the autovaccine (figure
1). After another 24 hours and on visit 38, study partici-
pants underwent a final examination.
Instruments
Specific bronchial challenge was delivered via a medic aid
nebulizer and the aerosol provocation system APS powered
by compressed air (all by Viasys Inc., Wuerzburg/Ger-
many). Exhaled nitric oxide (eNO) as a surrogate for bron-
chial inflammation was determined using a NO-analyzer
(NIOX
®, Aerocrine Inc., Stockholm/Sweden) according to
the criteria of the American Thoracic Society [13], before
starting any inhalation and 24 hrs after the challenge. In
order to control for intrasubject variability, the mean values
of three consecutive measurements were taken.
Therapeutic intervention
The autovaccine produced by Symbiovaccin, Herborn/
Germany is a patient-specific E.coli autovaccine, which
has been used for decades in many European countries.
Apathogen E.coli is isolated from the patient’sf e c e s ,p r o -
cessed according to a standardized procedure and twice
heat-inactivated (75°C) over two hours [14] with level 1
containing 1 × 10
8 -1×1 0
9 units germs/ml, level 2 con-
taining 1 × 10
7 -1×1 0
8 units germs/ml, level 3 contain-
ing 1 × 10
6 -1×1 0
7 units germs/ml, level 4 containing 1
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5 -1×1 0
6 units germs/ml, level 5 containing 1 × 10
4
-1×1 0
5 units germs/ml, level 6 containing 1 × 10
3 -1×
10
4 units germs/ml. Additionally, isotonic saline solution
(sterile, free from pyrogenes, 996.5 μl) and Phenol lique-
factum 3.5 mg as preservative. The immunization sche-
dule starts with level 6 and concentrations increase up to
level 1; in case of intolerance towards the autovaccine,
increase of doses was slowed down, or concentrations
went back to the last tolerated step for two weeks. If this
did not result in tolerance of the autovaccine, or severe
side effects occurred, the participant would have dropped
out of the study.
Outcomes and laboratory testing
Primary outcome measures were the occurrence of
adverse events, the tolerability of the intervention, and
safety laboratory testing including clinical chemistry
( C r P ,G O T ,G P T ,y - G T ,a P ,c r e a t i n i n e ,a n du r e a ) ,
hemostasis (Quick, PTT, and fibrinogen), hematology
(red and white blood cell count, thrombocytes), markers
of kidney function (urine-stix, beta-microglobuline), and
the electrocardiogram. Theseb l o o da n du r i n et e s t i n g s
were performed on each visit. Secondary outcome para-
meter were the impact of the autovaccine treatment on
exhalative nitric oxide as a marker for bronchial inflam-
mation, and the impact on markers of allergy (eosino-
philic cationic protein (ECP), total IgE, and specific IgE
against house dust mite Der. p1.a n dDer. far., which
were determined at the beginning of the study (visit 0)
and after the intervention (visit 37).
Statistical analysis
Since this study was a pilot study investigating safety
and tolerability, analysis was mainly based on descriptive
approaches. In the absence of normally distributed
values, medians and standard deviations (SDs) were cal-
culated for every visit. Also the analysis of exhalative
nitric oxide values was performed by non-parametric
tests (Mann-Whitney, Wilcoxon). A probability (p)-level
< 0.05 was considered as statistically significant.
Results
Baseline characteristics of participants
A total of 15 subjects were screened, of which nine
(female:male = 6:3) could be included into the study. The
other six subjects considered the protocol as too time
consuming. Eight subjects completed the study with
100% adherence to all visits; one subject (No. 2) dropped
out due to urticaria, which had also been observed before
the study started (table 1). All participants used short-
acting betamimetics on demand without change of the
dosage or frequency in the course of the study. Measur-
ing of peak flow revealed no negative acute impact of the
autovaccine application on the lung function.
Local reactions
Erythema a tt h ei n j e c t i o ns i t ea sa ne x p r e s s i o no fa
local immune reaction was observed in every patient,
starting from different dosage levels (see table 2). In a
total of 306 injections, we observed 101 episodes of
erythema (33%) with a median of 12/36 injections per
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Figure 1 Autologous E. coli autovaccine in house dust mite asthma. Figure 1 illustrates the study design of the trial
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Page 3 of 8patient (range 1-26), with a median maximal diameter of
2.5 cm (range 2-11 cm).
Swelling at the injection site occurred in eight of nine
subjects, starting from different dosage levels. Among
306 injections, we observed a total of 95 episodes of
swelling (31%). There was a median of 10 swellings/36
injections per patient (range 0-25), with a median of the
maximal diameter of 3 cm (range 0-11 cm).
Local pain was reported by four of nine patients. In
contrast to erythema and induration, which were
observed repeatedly after reaching the reaction level,
local pain recurred only in two subjects, while two other
subjects reported local pain only once each (probably by
accidental irritation of a skin nerve by the needle).
Among 306 injections, 27 episodes of local pain (8.8%)
were reported, among them 20 episodes in one subject
and 1 episode each in two subjects in the middle of the
study, without further reporting in the continuation of
the study.
Itching at the injection site was reported by four of
nine subjects. It occurred in 30/306 injections (9.8%).
Urticaria exclusively occurred in subject No. 2 start-
ing from visit 16 and upon mechanical irritation of the
skin, disappearing with dose-reduction and reoccurring
after increasing concentrations of the autovaccine. The
patient reported similar episodes of urticaria already in
the past. Despite the mild character of the complaints,
the patient was excluded from the study.
In the course of the study, one female subject experi-
enced a urinary tract infection, which was considered as
not causally related. We observed no other serious
adverse events. All organ functions (inclusive electro-
cardiogramm) and laboratory testing of the blood (clini-
cal chemistry, hematology) and the urine (screening test,
B-microglobuline) were within normal limits.
Vital signs undulated within the physiological varia-
bility (see table 3). The peak-flow measurement follow-
ing each visit revealed no negative impact of the
autovaccine on acute lung function.
Blood and urine testing, ECG
The markers of clinical chemistry (CrP, GOT, GPT, y-
GT, aP, creatinine, and urea), hemostasis (Quick, PTT,
Table 1 Features of the study population
subject
No.
gender age
[years]
height
[cm]
weight
[kg]
BMI FEV1
[%]
therapy Asthma
severity
1 female 27 161 52 20.1 98.0 BoD <1/w
2 female 27 170 64 22.1 104.0 BoD <1/w
3 female 29 170 70 24.2 94.0 - <1/w
4 female 28 166 54 19.6 109.0 - <1/w
5 male 22 187 85 24.3 127.0 - <1/w
6 male 34 176 80 25.8 118.0 - <1/w
7 female 27 166 59 21.4 82.7 BoD <1/w
8 female 31 180 66 20.4 97.0 - <1/w
9 female 49 163 65 24.4 99.0 BoD <1/w
BoD = betamimetic inhalation on demand; <1/w = less than one exacerbation/week & no limitation of activities
Table 2 Local reactions after autologous E.coli autovaccine
Subject Erythema Induration Local pain* Itch
No. 1 V32 ® V32 ® V32 ® -
No. 2 V16 ® -- -
No. 3 V22 ® V23 ® V22 -
No. 4 V25 ® V25 ® --
No. 5 V29 ® V29 ® --
No. 6 V26 ® V26 ® - V26 ®
No. 7 V22 ® V22 ® V22 V31 ®
No. 8 V13 ® V13 ® - V8/16/25; V27 ®
No. 9 V9 ® V9 ® V17 ®-V 9
episodes total No. (per 306 injections) 101 (33%) 95 (31%) 27 (8.8%) 30 (9.8%)
episodes/subject [median No., range] 12 (1-26) 10 (0-25) n.a. n.a.
average size [cm, range] 2.5 (2-11) 3.0 (0-11) n.a. n.a.
V32 ® = after visit 32 and every following visit; V22 = after visit 22; * = mild in character; n.a. = not applicable
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count, thrombocytes), and of kidney function (urine-stix,
beta-microglobuline) undulated within the physiological
and laboratory variability and indicated no negative
impact of the autovaccine treatment (tables 4, 5). The
electrocardiogram before, during and after autovaccine
treatment remained unchanged.
Markers of Allergy
The determination of allergy markers before (visit 0)
and after autologous autovaccine treatment (visit 37)
revealed a reduction without reaching statistical signifi-
cance. Median levels (Q25, Q75) of the eosinophilic
cationic protein (ECP) decreased from 22.7 (9.45, 36.9)
μg/ml to 17.7 (9.53, 21.8) μg/ml (p = 0.144). Median
levels of IgE decreased from 206 (47, 261) IU/ml to 127
(81, 152) IU/ml (p = 0.490). Specific IgE against Der. p1.
decreased from 30.5 (8.96-46.1) to 28.3 (12.3-40.9) IU/
ml (p = 0.468), against Der. far. from 28.1 (6.67. 43,1) to
23.1 (9.93, 45.9) IU/ml (p = 0.489).
Exhaled Nitric Oxide
Median (25
th and 75
th quartile) values of exhaled nitric
oxide at visit 0 were 32.6 (20.8-37.4) before house dust
mite challenge, and 42.2 (28.2-75.8) ppb, corresponding
with a 1.36-fold increase (p = 0.046). After the autovac-
cine treatment at visit 37, basal median eNO was 27.3
(13.4-51.0) ppb and increased within 24 hrs to 33.8
(14.1-56.0) ppb, corresponding to a 1.13-fold increase (p
= 0.334). Over all, the eNO increase before the autovac-
cine treatment was significantly higher than after the
intervention (p = 0.034; figure 2).
Discussion
As early as in the beginning of the last century, a sta-
phylococci autovaccine had been developed in England
[15]. The success of antibiotics made this mile stone dis-
appear, but in the last decades, especially Eastern Eur-
opean groups reported the successful usage of
autovaccine in the treatment of severe acne vulgaris,
chronic sinusitis, otitis media etc. [6-8].
In this first prospective clinical trial, which was
focused on safety and tolerability, we also observed a
mild but significant reduction of the exhaled nitric
oxide as a surrogate marker for bronchial inflammation.
As expected, in the beginning of the study values of
eNO increased significantly after bronchial mite chal-
lenge. After 37 weeks and autovaccine treatment, eNO-
values were lower before and after the challenge; also
the increase due to the provocation was significantly
lower. This goes with Halasa and coworkers from the
University of Stettin, who have been treating bronchial
asthma with autovaccine over decades [16].
In the autovaccine treatment, a typical acute-phase
reaction with a rapid inflammatory response can be
observed with the deliberation of various mediators [17].
Besides this unspecific phenomenon, also specific
responses can be induced. Following an autovaccine
derived from Propionibacterium acnes, specific antibo-
dies against structural antigens of P. acnes could be pro-
ven [6].
Also an activation of antigen-specific T-helper cell-
subpopulations could be observed [7]. The underlying
immunological mechanisms could be illuminated in ani-
mal models. C57BL/6-mice were sensitized with ovalbu-
min, resulting in bronchial hyperresponsiveness. Then,
they were treated with autovaccine, and following an
aerosolprovocation, bronchial hyperreactivity was found
to be blocked. Autopsy revealed a significant suppres-
sion of specific IgG-1-antibodies, and a reduced bron-
chial inflammation as illustrated by a reduction of
eosinophils and lymphocytes in the bronchoalveolar
Table 3 Vital signs after autologous E.coli autovaccine
application
Heartbeat/min. Body temperature [°C]
0’ 30’ 60’ 90’ 120’ 0’ 30’ 60’ 90’ 120’
Subject No. 1
median 75.0 72.0 74.0 75.0 72.0 36.4 36.2 36.2 36.4 36.4
SD 6.03 6.55 5.31 5.15 5.27 0.68 0.69 0.64 0.62 0.57
Subject No. 2
median 86.0 83.5 83.0 80.0 77.5 36.8 37.0 37.0 36.9 36.8
SD 6.55 12.2 11.2 12.5 9.72 0.32 0.309 0.207 0.2 0.19
Subject No. 3
median 64.0 64.0 62.0 58.0 59.0 36.2 36.3 36.3 36.4 36.2
SD 8.88 5.4 5.60 8.16 5.66 0.34 0.30 0.31 0.38 0.27
Subject No. 4
median 64 80 78.5 80 78 36.4 36.5 36.7 36.6 36.7
SD 16.0 12.5 13.2 7.8 8.48 0.29 0.37 0.54 0.33 0.29
Subject No. 5
median 76 69.5 70.5 69.0 66.0 36.2 36.3 36.2 36.4 36.3
SD 10.2 12.6 11.7 11.8 7.87 0.20 0.30 0.19 0.26 0.16
Subject No. 6
median 79.0 76.0 74.5 74.0 73.5 36.2 36.20 36.2 36.3 36.3
SD 11.0 7.94 5.82 4.63 5.17 0.22 0.26 0.30 0.27 0.31
Subject No. 7
median 75.0 75.0 68.5 74.5 73.0 36.4 36.2 36.2 36.1 36.2
SD 4.90 5.97 7.87 5.72 5.43 0.33 0.29 0.29 0.21 0.37
Subject No. 8
median 80 80 80 79.5 80 36.1 36.1 36.1 36.1 36.1
SD 6.35 6.16 6.65 7.23 5.81 0.05 0.05 0.05 0.04 0.05
Subject No. 9
median 72 68 68 68 68 36.1 36.1 36.1 36.1 36.1
SD 9.70 10.1 9.51 8.35 8.51 0.05 0.05 0.06 0.04 0.04
SD = standard deviation
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subject Hb Hkt MCV Erys Leuc Thromb Lymph Monos Neutr Eos Basos
No. 1 median 11.7 37 84.5 4.48 6.6 364 36.8 5.2 53.5 3.6 0.7
SD 0.65 1.89 1.60 0.18 1.10 31.2 6.08 0.87 6.49 1.14 0.37
No.2 median 12.3 37.9 87.1 4.3 5.6 328.6 29.6 4.1 48.3 1.8 0.4
SD 5.7 17.6 40.1 2.0 2.7 15.5 14.4 2.0 22.8 1.3 0.3
No.3 median 13.2 37.6 90.8 4.13 5.87 226.5 36.4 4 54.9 4.4 0.3
SD 0.54 1.32 1.20 0.17 0.84 21.2 5.95 0.81 6.84 1.16 0.20
No.4 median 14.1 41.75 87.4 4.78 5.62 209 42.5 4.4 49.7 3.1 0.6
SD 0.40 1.31 0.84 0.12 0.86 15.1 5.28 0.64 5.66 0.83 0.33
No.5 median 14.3 41.5 86.7 4.81 4.62 264 30.9 9 55 4.8 0.8
SD 0.67 1.56 1.65 0.15 0.92 14.5 4.69 1.27 5.77 1.57 0.60
No.6 median 15.9 45.9 85.9 5.35 5.79 207 44.1 5.7 40.4 8 0.6
SD 0.49 1.35 0.74 0.17 1.11 12.1 7.00 1.10 7.32 2.25 0.33
No.7 median 12.1 35.9 86.6 4.16 3.96 236 38.5 5.4 54 1.5 0.3
SD 0.48 1.49 1.45 0.15 0.62 23.7 5.96 0.97 6.68 0.58 0.31
No.8 median 12.8 38.1 89.3 29.6 33.2 4.29 7.24 329 37.0 4.9 55.1
SD 0.60 1.79 1.48 0.65 0.41 0.23 1.39 23.1 5.67 0.87 6.17
No.9 median 12.2 35.6 88.3 30.4 34.5 4.04 5.1 303 36.5 6.0 55.4
SD 0.47 2.07 0.83 0.45 0.64 0.14 0.72 23.7 4.59 0.92 5.23
Hb = haemoglobine [g/dl]; MCV = mean corpuscular volume [fl]; Erys = eythrocytes [10
6/ml]; Leuc = leucozytes [1000/ml]; Lymph = lymphocytes [%]; Monos =
monocytic granulocytes [%]; Neutr = neutrophilic granulocytes [%]; Eos = eosinophilic granulocytes [%]; Basos = basophilic granulocytes [%]; SD = standard
deviation
Table 5 Laboratory testing - clinical chemistry
subject Quick PTT Fib GOT GGT GPT AP CRP Krea Bun ß2 Mikrog
No. 1 median 87 33 247 20 20 12 22 0.09 0.69 20 1.3
SD 5.98 1.44 30.3 3.56 2.87 4.69 4.02 0.05 0.07 3.92 0.13
No.2 median 82.9 31.8 219.0 16.7 18.4 8.2 17.7 0.1 0.6 16.1 1.2
SD 3.84 14.9 12.6 8.5 8.8 5.2 8.9 0.0 0.3 7.8 0.5
No.3 median 90 35 235 22 12 15 35 0.03 1.06 29.5 1.4
SD 4.61 1.43 46.1 2.70 2.02 2.54 4.59 0.36 0.07 5.30 0.13
No.4 median 96.5 30 275.5 25 21 18 52 0.06 0.79 24 1.2
SD 5.12 1.47 38.1 3.10 2.36 5.02 5.70 0.20 0.07 3.93 0.08
No.5 median 92 33 232 27 15 22 66 0.04 0.99 29 1.7
SD 4.71 1.04 41.9 5.20 1.08 4.68 4.39 0.12 0.09 3.12 0.15
No.6 median 108 33 283.5 20 30 18 58 0.05 0.93 28 1.3
SD 4.64 1.81 44.2 2.66 1.73 2.26 7.52 0.09 0.05 5.64 0.13
No.7 median 91 34 293 21 42 18 49 0.21 0.74 27 1.75
SD 3.91 0.94 27.8 1.92 3.81 2.47 6.21 0.15 0.07 3.18 0.13
No.8 median 110 31 244 19 39 20 83 0.07 1.01 33 1.6
SD 6.99 1.92 23.8 2.31 3.89 3.26 6.58 0.22 0.07 5.11 0.09
No.9 median 88 33 220 21 11 14 34 0.05 0.63 24 1.3
SD 4.52 1.15 23.2 1.77 2.09 1.91 2.08 0.06 0.07 3.99 0.097
Quick = thromboplastin time [%]; PTT = partial thromboplastin time [sec.]; Fib = fibrinogen [mg/dl]; GOT = aspartat aminotransferase [U/l]; yGT = gamma
glutamyltransferase [U/l]; GPT = alanin aminotransferase [U/l]; AP = alkaline phosphatase [U/ml]; CrP = C-reactive protein [mg/dl]; Krea = creatinine [mg/dl]; Bun =
urea [mg/dl]; ß2 Mikrogl = ß2 microglobuline [mg/l]; SD = standard deviation
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inflammatory IL-10 and IFN-y [18].
Autovaccines have been used for more than a century
in veterinary and human medicine worldwide. Estab-
lished indications are chronic infections of the airways
and associated sinuses, the skin (furunculosis), and the
bones (osteomyelitis) [e.g., 9]. A Tschec study demon-
strated in 33 patients with chronic upper airway infec-
tions a therapeutic success of the autovaccine, persisting
over three years of follow-up [10].
Another trial from Poland prospectively treated 292
children suffering from sinusitis showed a success of
autologous autovaccine in 88% of the patients [7]. A
Russian group successfully treated sinusitis ethmoidalis
with autovaccine [9]. In Germany, a study demonstrated
the autovaccine’s usefulness in cows suffering from geni-
tal infections [11].
So far, only one GCP-conform clinical trial has been
performed, treating 78 adult patients suffering from var-
ious infections (32% skin, 42% airways) with E. coli auto-
vaccine and demonstrating good tolerability. Within this
study, blood of patients underwent an ex vivo stimula-
tion of leucocytes with autovaccine, inducing a decrease
of the cytokines GM-CSF and INF-y, while IL-1ß and
IL-6 increased [19].
Patients suffering from allergic asthma typically react
upon bronchial challenge with their specific allergen
with a deterioration of their lung function and with clin-
ical complaints (e.g., cough). We could demonstrate in
an antecedent study the protective effect of anti-inflam-
matory polyunsaturated fatty acids as to bronchial
response upon a bronchial house dust mite challenge
[19]. We postulate that also the anti-inflammatory effect
of autovaccine can be investigated analogously. In addi-
tion, the determination of eNO is an established surro-
gate marker for airway inflammation.
Just like in other immunotherapies, local (at the injec-
tion site) and systemical side effects can occur [20]. In
addition, with incremental dose often an individual
“reaction threshold” is observed, showing profound reac-
tions at the injection site within 24 hours, in rare cases
also systemic reactions (irritation, pain, and an increase
of body temperature). No other severe side effects have
been observed so far in clinical routine. Autologous
autovaccine had no negative acute impact on the lung
function as proven by peak flow measurements after the
application. In contrast, we observed mild positive
effects on markers of allergic inflammation (eNO, ECP,
IgE). Our study is the first to prospectively investigate a
substance which has been used for decades in comple-
mentary medicinal practice. We estimated risks and side
effects to be comparable with the established specific
immunotherapy, but in contrast to SIT, we did not
expect allergic reactions upon a specific allergen [21].
Our study demonstrated a good tolerability of the auto-
logous autovaccine in the treatment of mild to moderate
bronchial asthma in the context of a house dust mite
allergy. We found a low number of local reactions and -
with the exception of one urticaria factitia (urticaria
upon mechanical pressure) no systemic side effects. The
affected person had already intermittently experienced
urticaria ahead of the study. Nonetheless, since the urti-
caria disappeared in parallel with the withdrawal of the
study medication and reoccurred with the re-challenge,
we judged it as potentially causal related. This goes with
the observation of urticaria occurring as an autoim-
mune-phenomenon. Since the aim of immunotherapy is
a shift towards a TH-1 dominated immune response,
autoimmune phenomena, which are perceived as TH1-
overregulations, might occur in this context. On the
other hand, it might have been the spontaneous and
natural course of the urticaria in an individual with
recurrent urticaria.
We observed the individually varying “threshold of
reaction” as described by the manufacturer and many
applying physicians only in very mild forms. In a few
cases and intermittently, the injection was perceived as
painful, what we interpreted as mechanical irritation due
to the injection needle, and independent of the autovac-
cine. We observed - as expected- mild local reactions as
an expression of immunological activation, but no clas-
sical allergic or anaphylactic reactions, with the restric-
tion, that due to the limited number of applications we
might have missed such relatively rare events. Thus, we
cannot come to a conclusive judgment of this aspect of
drug safety. As with all studies, we relied on accurate
reporting of symptoms and complaints and accepted the
limitations of this approach as to our primary endpoints.
Also the small number of the analysed group might
have resulted in type 2 errors.
Figure 2 Impact of E.coli autovaccine on exhaled NO as marker
of bronchial inflammation in house dust mite allergic asthma.
Figure 2 illustrates the increase of exhaled nitric oxide under specific
bronchial challenge before and after autovaccine application
Rose et al. BMC Complementary and Alternative Medicine 2011, 11:45
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Page 7 of 8Over all, our study underlines the experiences with
autovaccine application from daily medical practice. It
seems that its tolerability is even superior to the estab-
lished conventional allergen specific immunotherapy.
Conclusions
In patients with house dust mite asthma, an incremental
schedule of autologous autovaccine was safe and well-
tolerated. Although specific immunotherapy (SIT)
already exists, autologous autovaccine might be an inter-
esting option in multiple allergies, where SIT is not
working. The observed impact on bronchial inflamma-
tion as expressed by a reduced increase of exhaled nitric
oxide will be the issue of a larger placebo-controlled
study.
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